• Do Patients Continue Behavioral, Relaxation, and Dietary Strategies for IBS?

Do Patients Continue Behavioral, Relaxation, and Dietary Strategies for IBS?

A combination of cognitive behavioral therapy, relaxation, and dietary strategies reduced symptoms and increased quality of life in patients with irritable bowel syndrome (IBS), compared with usual care, researchers report in the February issue of Clinical Gastroenterology and Hepatology. The program produced sustainable behavioral changes in almost all participants after

Read more
  • Can a Cocktail Prevent Colorectal Adenoma Recurrence?

Can a Cocktail Prevent Colorectal Adenoma Recurrence?

The combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period, found a prospective study published in the January issue of Gastroenterology. This negative result might have been affected by the numbers of smokers included in the study or low doses of

Read more
  • Do Proton Pump Inhibitors Reduce the Need for Phlebotomy in Patients With Hereditary Hemochromatosis?

Do Proton Pump Inhibitors Reduce the Need for Phlebotomy in Patients With Hereditary Hemochromatosis?

In certain patients with hereditary hemochromatosis (HH), treatment with proton pump inhibitors (PPIs) for 2 or more years significantly reduced the number of phlebotomies required to maintain serum levels below 100 μg/L, researchers report in the January issue of Clinical Gastroenterology and Hepatology. HH is one of the most common

Read more
  • Is Combination Therapy Most Effective for HBV Infection?

Is Combination Therapy Most Effective for HBV Infection?

A significantly greater proportion of patients receiving a combination of tenofovir disoproxil fumarate (TDF) and pegylated interferon-α (peginterferon) for 48 weeks lost hepatitis B surface antigen (HBsAg), a marker of hepatitis B virus (HBV) DNA transcriptional activity, compared to patients given the standard care (peginterferon or TDF alone), researchers report

Read more
  • Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

In Egypt, pharmaceutical companies are testing a complicated deal to sell hepatitis C drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West. According to the New York Times, Gilead Sciences Inc. is selling its sofosbuvir to the Egyptian government

Read more
  • What is the Best way to Manage Diverticulitis, and how Many People Have it?

What is the Best way to Manage Diverticulitis, and how Many People Have it?

Not all patients with multiple episodes of diverticulitis should undergo preventative surgery, shows a Markov decision model published in the January 2016 issue of Clinical Gastroenterology and Hepatology. Elective surgery after 2 episodes produces fewer quality-adjusted life-years (QALYs) than surgery after 3 episodes or conservative or medical treatments, the model found.

Read more

New Treatment Approved by FDA for Lysosomal Acid Lipase Deficiency

The Food and Drug Administration (FDA) approved a drug called sebelipase alfa (Kanuma) as the first-ever treatment for lysosomal acid lipase deficiency (LAL)—a rare inherited disorder. LAL deficiency causes a build-up of fats within the cells of various tissues that can lead to liver and cardiovascular diseases and other complications.

Read more

Should Patients with Crohn’s Disease Continue Receiving Immunomodulators When Starting Anti-TNF Therapy?

Continued use of immunomodulator therapy in patients with Crohn’s disease receiving anti-tumor necrosis factor (TNF) therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission, researchers show. The meta-analysis of randomized controlled trials is published in the December issue of Clinical Gastroenterology and Hepatology. There is debate

Read more
  • Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid programs in Delaware, Maryland, New Jersey, and Pennsylvania denied nearly half of all claims in the past year for direct-acting antiviral (DAA) hepatitis C drugs, according to an analysis of pharmacy data presented at the American Association for the Study of Liver Diseases 2015 Liver Meeting. The finding confirms

Read more
  • Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Specific groups of intestinal microbes can boost the anti-tumor effects of cancer immunotherapies in mice, researchers show. Cancer immunotherapies that block immune inhibitory pathways have been tested in patients with several tumor types, but responses have varied. A study published in Science, while not the first to link gut microbes

Read more